Compare TRST & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | MNKD |
|---|---|---|
| Founded | 1902 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.9M | 877.0M |
| IPO Year | 1994 | 2004 |
| Metric | TRST | MNKD |
|---|---|---|
| Price | $50.48 | $3.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 67.4K | ★ 6.0M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 26.46 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | $55.44 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $30.17 | $2.23 |
| 52 Week High | $50.52 | $6.51 |
| Indicator | TRST | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 59.70 |
| Support Level | $41.96 | $2.45 |
| Resistance Level | N/A | $6.08 |
| Average True Range (ATR) | 0.89 | 0.26 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 82.95 | 34.25 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.